L'obésité concerne 13 % de la population mondiale. © Jakub Cejpeck, Shutterstock

An antidepressant drug can also help you lose weight

A type 2 diabetes drug has also allowed obese patients to lose weight after more than a year of treatment. This is the result of a clinical trial at Yale University.

According to the World Health Organization (WHO), 13% of the world’s population suffers fromobesity (a BMI more than 30 million, or more than 600 million people. If the figure on the scales does not necessarily reflect the health of the person on board, obesity is known to promote the onset of disease chronic as the diabetes type 2, thehypertension and other health problems that can decrease thelife expectancy.

A drug already licensed to treat type 2 diabetes, tirzepatide, has allowed participants one clinical trials led by doctors at Yale University of lose weight significantly. The drug was tested according to three dosages different – 5, 10 and 15 mg – and injected under the skin once a week for 72 weeks. The 2,500 patients are all obese, with an average weight of 104 pounds, and also have at least one complication related to their weight. Diabetic patients are excluded from the clinical trial, but those with pre-diabetes have been included.

An effective anti-diabetic for weight loss

Participants treated with 5 mg tirzepatide lost an average of 15% masses At the end of 72 weeks, those who took 10 and 15 mg lost 19.5 and 20.9% of their body weight, respectively. This is only 3% for people who have received one placebo. On average, tirzepatide reduced participants’ fat mass by 33.9%, improving the fat-to-weight-to-weight ratio and bringing it closer to that of sports-based weight loss strategies. and food or the surgery. In addition to the decrease in body mass, tirzepatide has been used to restore the blood sugar in normal values ​​in pre-diabetic patients. This could reduce the risk of developing one cardiovascular diseasekidney, liver and type 2 diabetes.

On the side effects, tirzepatide caused side effects symptoms gastrointestinal disorders such as nausea, vomiting diarrhea and des constipation of mild to moderate severity. Eleven people died during the duration of the clinical trial, both in the placebo group and in the treatment group. As the clinical trial ran from December 2019 to April 2022, several participants died from Covid-19, others pulmonary embolisma Stroke or a cardiac arrest. Deaths that do not appear to be directly related to tirzepatide. Further results are needed for tirzepatide to obtain a marketing authorization as part of the treatment of obesity.

Special offer: for Father’s Day, offer the best of Science!

Your father is a great man passionate about Science and unusual discoveries? What if you offered him one superb scientific exploration on paper? Get -20% off on the Future Mag (special offer: € 15 instead of € 19): 220 pages to explore 4 scientific issues that will shape our future!

The Mag Futura is:

  • 4 major scientific questions for 2022, from Earth to the Moon
  • 220 pages, 60 experts: no fake news, just Science
  • Home delivery with electronic gift card
  • An independent scientific medium

Interested in what you just read?


Leave a Comment

Your email address will not be published.